We begin our week at BIO 2026 focusing on inspiration not just as a “nice to have,” but as an essential tool for leading teams through the extreme pressures of our industry. Our executive breakfast kicks off with Danielle Baldwin, executive coach and author of Sparking Greatness, who will challenge us to rethink inspiration as a deliberate act, not just something we wait for to strike. Following her remarks, Danielle will moderate our panel of seasoned executives who will translate these insights into real-world applications. Drawing on experience across research, commercial, regulatory, and operations, the discussion will focus on how to:

• Motivate and engage teams when the stakes are high and the path is unclear.
• Lead through uncertainty, moving beyond “getting it done” to “igniting the best” in others.
• Navigate complexity to drive innovation and advance commercialization in today’s landscape.

Don’t miss this chance to start your week with a toolkit for leading courageously.

Program

9:00 a.m. – 9:25 a.m.  Breakfast Buffet / Networking
9:25 a.m. – 9:30 a.m.  Welcome Remarks
9:30 a.m. – 9:40 a.m.  Danielle Baldwin
9:40 a.m. – 10:30 a.m.  Panel Discussion
10:30 a.m. – 11:00 a.m.  Networking

Speaker Bios

Danielle Baldwin, Executive Coach & Author

Danielle is a speaker, writer, and coach who helps leaders and teams spark clarity, courage, and connection, both at work and beyond. As the author of Sparking Greatness, she explores how inspiration works and how to create the conditions for it to spread.

Stacy Feld, Global Head of External Scientific Innovation at Johnson & Johnson

For nearly three decades, Stacy has been driven by a passion for translating bold ideas into impactful healthcare solutions to transform human health. Stacy is Global Head of External Scientific Innovation at Johnson & Johnson, where she is responsible for advancing J&J Innovative Medicine’s discovery and development pipeline through early-stage external partnerships and company incubation across the global life science and health technology ecosystem. She leads a global team of science and business leaders to source, incubate, and partner with entrepreneurs and external partners across the early-stage innovation landscape to accelerate long-term growth strategies, pipeline value, and patient benefit. With diverse experience in technology licensing, business development, and venture investment spanning biotech, medtech, and consumer and digital health, Stacy is a recognized leader for shaping innovation strategies and ecosystems and fostering science-driven collaborations that create near- and long-term impact. A frequent speaker and advisor across the life sciences and biotech landscape, Stacy currently serves on the Investment Advisory Committee for organizations such as J&J Impact Ventures, the American Heart Association Go Red for Women Fund, and RH Capital. Stacy earned her BA in sociology from the University of Pennsylvania and her JD from Vanderbilt Law School.

Nancy Hong, PhD, Biotech Investor

Nancy is a life science investor with a technical background, operating experience, and varied GP and LP investing roles. She was a VC investor at RiverVest Venture Partners, BioMed Ventures, and Forward Ventures. She began her biotech career as a scientist at Phenomix Corp. She has a PhD in molecular immunology and conducted postdoctoral research in oncology. She is currently on the board of the San Diego Symphony Orchestra.

Sabrina Martucci Johnson, President & CEO of Daré Bioscience

Sabrina is one of the most determined voices in women’s health, and one of the few willing to bet her career on it. In 2015, when venture capital had largely abandoned women’s health, Sabrina founded Daré Bioscience (NASDAQ: DARE), a clinical-stage biopharmaceutical company built on a single, uncompromising premise: women deserve better. Not incrementally better. Categorically better. From contraception and menopause to vaginal health, sexual health, fertility, and infectious disease, Daré is closing the gaps that a generations-long underinvestment in women’s biology left behind. Under her leadership, Daré has built a capital-efficient pipeline powered by rigorous science, landmark non-dilutive funding — including grants from the Gates Foundation, ARPA-H, and NIH — and a dual-path commercialization strategy designed to get innovations to women faster. The company is now at an inflection point: multiple products launching in 2026, and multiple first-in-category product candidates in development. Sabrina brings rare range to this mission. She began her career as a research scientist at Baxter Healthcare working on the recombinant factor VIII program, then built operational and financial expertise across Advanced Tissue Sciences, Cypress Bioscience (NASDAQ: CYPB), the California Institute for Biomedical Research, and WomanCare Global — a global women’s health products company she led as President. That combination of bench science, finance, and commercial execution informs how she builds: with rigor, urgency, and zero tolerance for the status quo.

Karen West, General Manager/Managing Director for Australia and New Zealand for Syneos Health

Karen is General Manager/Managing Director for Australia and New Zealand within the clinical development team at Syneos Health. Karen has over 30 years of experience in the clinical trial industry, including global CRO, pharmaceutical company, site, and local CRO experience. Karen has held a number of positions throughout her career within the clinical trial fields of clinical operations, project management, biometrics, training, business development, and executive and strategic management. Karen has worked across all phases of clinical development through to large-scale Phase 3 multi-country studies with extensive experience, particularly in the phase I and first-in-human space. Karen has managed large teams within APAC and also globally, including teams in North America and Europe. She has led teams across multi-functional areas, including project management, clinical operations, business development/proposals, biometrics, and medical writing. In 2023, Karen was appointed as the inaugural General Manager/Managing Director for Australia and New Zealand for Syneos Health. In this role, Karen acts as the local Australian and NZ-based advocate and support for local ANZ biotechs and pharmaceutical companies, as well as global companies looking to conduct work in Australia and New Zealand. Karen is passionate about promoting Australian and New Zealand clinical trial capabilities globally, often presenting at global conferences and roadshows.

Pricing Information

• Members: $55
• Non-Members*: $85

*Not a Member? Click here to purchase a WIB membership and gain access to our video library, mentorship opportunities, and more. 

Please read WIB’s Code of Conduct and Refund Policy.

Note: A confirmation email will be sent after registration has been completed. 

Registration Deadline

June 17, 2026

Parking Information

Parking is available at the underground parking garage. A ticket will be issued upon entry and can be paid for at a kiosk in the garage or upon exit.